Trial Profile
A Randomized, Three-treatment, Three-period, Six-sequence Crossover, Single-center, Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2019
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Endometrial cancer; Liver cancer; Non-small cell lung cancer; Renal cancer; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 30 Oct 2015 New trial record